GLEN BURNIE, MD, November 28, 2018 – Vision Technologies, Inc. (Vision), a leading systems integrator, recognizes the importance of giving back to the community. Each year, Vision selects a charity to support and makes an impact through various fundraisers. The Tragedy Assistance Program for Survivors (TAPS) was at the top of Vision’s list for its Making Giving a Reality campaign in 2018, with Vision and its teammates donating over $70,000! ...  Read more

CyByte, a software development company, is pleased to announce their investment in VideoKall, a telehealth provider.
VideoKall is a telemedicine platform provider and operator specializing in enabling medical providers to offer healthcare services to patients in micro-clinic booths at convenient locations, wherever they live, work, travel, go to school or shop.
Neeraj Chitra, CEO of CyByte, said “this is an exciting time in healthcare, and CyByte is appreciative of VideoKall for combining our expertise with their innovative approach to better access and lower cost services.” The new software platform for VideoKall includes the major portions for the medical devices and subsystems in the CLINICSTOP® booth, but also the broadband videophone telecommunications, the call center equipment, the medical terminals and a new patient engagement mobile app. CyByte’s on-demand expertise has completed its first phase where recent tests confirmed that the desired outcomes are predictable and build off the lessons learned from VideoKall’s patented working prototype and the healthcare software expertise of CyByte. ...  Read more

ROCKVILLE, MD, September 14, 2018
Creatv MicroTech, Inc. (Creatv) has received a $625,000 award from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) to investigate their discovery of giant circulating cells found in peripheral blood for non-invasive detection of lung cancer by differentiating malignant from benign pulmonary nodules detected by low dose CT (LDCT). In the three-year study, Creatv will examine blood samples from 1,250 subjects at high risk for lung cancer based on their smoking history and occupational exposure to carcinogens. ...  Read more

GERMANTOWN, Md., Sept. 5, 2018 /PRNewswire/ — SERAXIS Inc., a privately held regenerative medicine company today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes. ...  Read more

Tech Entrepreneurs Outgrow Incubator, Welcome Room to Grow ...  Read more

FREDERICK, Md., Aug. 31, 2018 /PRNewswire-PRWeb/ — Rare blood disorders are on VERALOX Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc. (FITCI), launched in September 2017 with a mission to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). ...  Read more

CHICAGO, Aug. 14, 2018 /PRNewswire/ — Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation for the treatment of pediatric Tourette Syndrome (TS) in patients under 16 years of age. ...  Read more

Program

The BIO Investor Forum delivers a rich program that features corporate presentations and panel debates on the sweet spots and growth challenges facing the industry.  The BIO Investor Forum features: ...  Read more